Tag: research

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Thunes awarded Platinum for Best Cross-Border Platform and Gold for Best B2B Payments, recognising its position as the engine connecting disparate local and global...

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

BEIJING, June 25, 2026 /PRNewswire/ -- Chinese President Xi Jinping has called for solid measures to advance the modernization of agriculture and rural areas,...

SAN FRANCISCO, June 24, 2026 /PRNewswire/ -- The global digital health market is expected to witness significant expansion over the coming years, with the...

CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Therapeutic Apheresis Market size & share revenue was valued at approximately USD 3.84 Billion in 2025 and is expected to reach USD 4.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Terumo BCT Inc., Fresenius Kabi AG, Haemonetics Corporation, B. Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., Miltenyi Biotec GmbH, Nikkiso Co. Ltd., Kaneka Corporation, Mallinckrodt Pharmaceuticals (Uvadex/ECP), Photomedex Inc., Macopharma SAS and others.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Therapeutic Apheresis Market size & share revenue was valued at approximately USD 3.84 Billion in 2025 and is expected to reach USD 4.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Terumo BCT Inc., Fresenius Kabi AG, Haemonetics Corporation, B. Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., Miltenyi Biotec GmbH, Nikkiso Co. Ltd., Kaneka Corporation, Mallinckrodt Pharmaceuticals (Uvadex/ECP), Photomedex Inc., Macopharma SAS and others.

HONG KONG, June 25, 2026 (GLOBE NEWSWIRE) -- Guest Supply today announced a licensing agreement with RODA to manufacture and distribute RODA-branded skincare and personal care products across Asia Pacific for the hotel sector.

Global market projected to grow at a CAGR of 13.5% from 2026 to 2033 as pharmaceutical, food, and healthcare industries increasingly rely on advanced...

NEW YORK, June 25, 2026 /PRNewswire/ -- LinqAlpha, the AI company building the first multi-agent AI system for public markets, today announced that it...

HONG KONG, June 25, 2026 /PRNewswire/ -- Joyson Electronics (0699.HK / 600699.SH), a leading global provider of smart technology solutions, announced the official opening...